News | December 30, 2013

RaySearch, TomoTherapy Cancel License Agreement

December 30, 2013 — RaySearch Laboratories and TomoTherapy Inc. (now Accuray) entered a software licensing and development agreement in 2007, under which RaySearch developed a product named SharePlan. TomoTherapy launched Shareplan in 2009.
 
SharePlan is a treatment planning solution that enables transfer of treatment plans between TomoTherapy systems and conventional linear accelerators. The product uses algorithms to automatically generate a selection of deliverable intensity-modulated radiation therapy (IMRT) plans based on an existing TomoTherapy treatment plan. This time-saving concept is a tool for optimizing patient benefit and throughput at clinics that have a mixed environment with both TomoTherapy systems and conventional linear accelerators.
 
Now RaySearch and Accuray have agreed to cancel the agreement and end the partnership. SharePlan functionality will continue to be available for new and existing customers as an integrated module in RaySearch’s RayStation treatment planning system that is sold and marketed by RaySearch. Existing SharePlan customers will be offered a free upgrade to RayStation.
 
“Since the original agreement was signed, a lot has changed for both companies, so this solution makes good sense for both parties,” said Johan Löf, CEO, RaySearch. “RayStation was not available four years ago, so back then a stand-alone application was the best solution. Now however, we can offer the same functionality in RayStation, which is evolving very rapidly and also gives the TomoTherapy System users the option to select other features and advanced treatment planning tools. This is attractive for the customers and Accuray alike, as it expands the product offering for these customers.”
 

Related Content

Proton Therapy Lowers Risk of Side Effects Compared to Conventional Radiation
News | Proton Therapy | May 23, 2019
Cancer patients getting proton therapy instead of traditional photon radiation are at a significantly lower risk of...
Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Varian Acquiring Cancer Treatment Services International
News | Radiation Therapy | May 21, 2019
Varian Medical Systems announced it has entered into a definitive agreement to acquire India’s Cancer Treatment...
Videos | Radiation Therapy | May 21, 2019
This is a walk through of the ViewRay MRIdian MRI-guided radiotherapy system installed at ...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
New Method Improves Ability to Measure and Maximize Radiation Therapy Dose
News | Radiation Therapy | May 14, 2019
Delivering just the right dose of radiation for cancer patients is a delicate balance in their treatment regime....
Sponsored Content | Videos | Radiation Oncology | May 13, 2019
At ASTRO 2018, Accuray showcased new patient-fi
Radiotherapy After Chemo May Improve Survival in Advanced Hodgkin's Lymphoma Patients
News | Radiation Therapy | May 10, 2019
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy...
IBA Partnering to Develop Advanced Digital Proton Therapy Technologies in Belgium
News | Proton Therapy | May 10, 2019
IBA (Ion Beam Applications SA) announced a research agreement with Skandionkliniken, Université Catholique de Louvain...